Cellectis SA Sponsored ADR
(NASDAQ : CLLS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
TSROTESARO, Inc.
-1.07%73.6914.4%$580.10m
AMGNAmgen Inc.
-2.76%192.071.2%$565.07m
GILDGilead Sciences, Inc.
-2.64%65.570.9%$530.36m
CELGCelgene Corporation
-2.21%68.201.2%$520.26m
BIIBBiogen Inc.
-1.75%314.551.3%$359.40m
ILMNIllumina, Inc.
-2.44%326.463.5%$350.15m
REGNRegeneron Pharmaceuticals, Inc.
0.70%381.172.6%$273.12m
VRTXVertex Pharmaceuticals Incorporated
-1.94%170.061.9%$226.47m
AAgilent Technologies, Inc.
-2.49%69.371.5%$225.54m
ALXNAlexion Pharmaceuticals, Inc.
-2.67%109.432.0%$146.61m
INCYIncyte Corporation
-1.55%66.252.5%$97.76m
EXASExact Sciences Corporation
0.68%68.3125.3%$93.39m
SRPTSarepta Therapeutics, Inc.
-2.05%119.5215.4%$90.77m
NKTRNektar Therapeutics
-3.92%36.515.5%$84.08m
SGENSeattle Genetics, Inc.
-0.85%60.486.6%$81.91m

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.